Breakthrough SARS-CoV-2 Infections in Patients With Immune-Mediated Disease Undergoing B Cell-Depleting Therapy: A Retrospective Cohort Analysis.

Cassandra M CalabreseElizabeth KirchnerM Elaine HusniBrandon P MossAnthony P FernandezYuxuan JinLeonard H Calabrese

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2022)

IMID patients receiving BCDT regardless of vaccine status appear to be vulnerable to infection with SARS-CoV-2, and use of BCDT is frequently associated with severe outcomes. Outpatient use of anti-SARS-CoV-2 monoclonal antibody therapy appears to be associated with enhanced clinical outcomes.

Keyphrases

sars cov
monoclonal antibody
respiratory syndrome coronavirus
stem cells
type diabetes
early onset
coronavirus disease
adipose tissue
insulin resistance
skeletal muscle
replacement therapy